David Saxon

Matthew Stanton

Vijay Kumar

Andrew Cooper

Brendan Smith

Jacob Johnson

Paul Knight

Hannah Hefley

Lucas Baranowski

Matthew Parisi

- Azenta reported **revenue from continuing operations** of **$144 million** for the third quarter of fiscal 2025, which was flat year-over-year.  **[933974_0001437749-25-024705_ex_818317.htm:0]** 
- For Q3 fiscal 2025, **diluted EPS from continuing operations** was **$0.01**, while **Non-GAAP diluted EPS from continuing operations** was **$0.19**.  **[933974_0001437749-25-024705_ex_818317.htm:0]**  Total diluted EPS was **($1.15)**, primarily due to a **$50 million non-cash impairment charge** related to discontinued operations.  **[933974_0001437749-25-024705_ex_818317.htm:0]** 
- The company ended the quarter with a total balance of **$565 million** in cash, cash equivalents, restricted cash, and marketable securities.  **[933974_0001437749-25-024705_ex_818317.htm:1]**  Operating cash flow was **$26 million**, and free cash flow was **$15 million** for the quarter.  **[933974_0001437749-25-024705_ex_818317.htm:1]** 
- Azenta **reiterated its full-year fiscal 2025 guidance**, expecting **total organic revenue growth** in the range of **3% to 5%** and **Adjusted EBITDA margin expansion** of approximately **300 basis points** relative to fiscal 2024.  **[933974_0001437749-25-024705_ex_818317.htm:1]**

Azenta Reports Q3 2025 Results and Reiterates Full Year Guidance

8e2372213b873ea0b75e6eb838f6efa70997060c306c16fde17eb35bfc4ce448

- Azenta reported **Q3 2025 revenue of $144 million**, flat year-over-year and **down (2%) organically**. **[933974_2054578:1]**  
- Non-GAAP diluted EPS from continuing operations was **$0.19**, while total diluted EPS was **($1.15)**, impacted by a **$50 million non-cash impairment charge** related to discontinued operations. **[933974_20250805LA44332:0]**  
- The company achieved an **Adjusted EBITDA margin of 12.3%** (Adjusted EBITDA of $18 million), marking a **260 basis point improvement** year over year. **[933974_20250805LA44332:0]** **[933974_20250805LA44332:1]**  
- Generated **$26 million in operating cash flow** and **$15 million in free cash flow**, ending with **$565 million in cash, cash equivalents, restricted cash, and marketable securities** and **no outstanding debt** as of June 30, 2025. **[933974_2054578:3]** **[933974_20250805LA44332:1]**  
- Segment performance included **3% organic growth in Multiomics** and a **6% decline in Sample Management Solutions**. **[933974_2054578:2]**  
- Management reaffirmed full-year fiscal 2025 guidance of **3–5% organic revenue growth** and **300 basis points of Adjusted EBITDA margin expansion**. **[933974_2054578:4]** **[933974_20250805LA44332:1]**

Azenta Reports Third Quarter Fiscal 2025 Results and Reaffirms Full-Year Guidance

f008b9add5840b54b69c56c92be0b47e12dcec1f9a8c7286a280b60b7903fb73

- Azenta reported **Q3 2025 revenue of $144 million**, which was flat year-over-year on a reported basis and **down (2%) organically**.  **[933974_2054578:1]** 
- The company achieved **Non-GAAP EPS of $0.19** and an **Adjusted EBITDA margin of 12.3%**, representing a **260 basis point year-over-year expansion**.  **[933974_2054578:1]** 
- Segment performance showed **3% organic growth in Multiomics** and a **6% organic decline in Sample Management Solutions**.  **[933974_2054578:1]** **[933974_2054578:2]** 
- Azenta maintains a strong balance sheet with a **cash balance of $565 million** and **no outstanding debt** as of June 30, 2025.  **[933974_2054578:3]** **[933974_2054578:4]** 
- For fiscal year 2025, the company expects **organic revenue growth of 3% to 5%** and **300 basis points of Adjusted EBITDA margin expansion**.  **[933974_2054578:4]**

Azenta reports Q3 2025 financial results

d5db042327e35161851df4b3629d146cc626b93603fbb2b1766df6f7ba672212

- Azenta reported **revenue from continuing operations of $144 million** for the third quarter ended June 30, 2025, which was flat year over year.  **[933974_20250805LA44332:0]** 
- The company's **Non-GAAP diluted EPS from continuing operations was $0.19**, while total diluted EPS was **($1.15)**, significantly impacted by a **$50 million** non-cash impairment charge related to discontinued operations.  **[933974_20250805LA44332:0]** 
- Azenta achieved **Adjusted EBITDA of $18 million** and an **Adjusted EBITDA margin of 12.3%** for the quarter, marking a **260 basis point improvement** year over year.  **[933974_20250805LA44332:0]** **[933974_20250805LA44332:1]** 
- The company generated **$26 million in operating cash flow** and **$15 million in free cash flow** during the quarter, ending with a total balance of **$565 million in cash, cash equivalents, restricted cash, and marketable securities** as of June 30, 2025.  **[933974_20250805LA44332:1]** 
- Management reiterated its **full-year fiscal 2025 guidance**, expecting total organic revenue growth in the range of **3% to 5%** and Adjusted EBITDA margin expansion of approximately **300 basis points** relative to fiscal 2024.  **[933974_20250805LA44332:1]**

e2f48a419792457d95f0de8fe9c96e4dab42e240714063a53bcde4262a8f8e86

988987e5416da3d733e9e3870b3fe1ae3608a730275b599f71b07fb8013e98a9

- Revenue from continuing operations reached **$143M**, reflecting a **5% YoY increase** driven by strong performance in key segments: **Sample Management Solutions ($80M, up 8%)** and **Multiomics ($64M, up 2%)** **[933974_1926440:1]** **[933974_0001437749-25-014901_ex_779225.htm:0]**.
- Earnings measures show contrasts: **non-GAAP EPS was $0.05** with a **10.0% adjusted EBITDA margin** and **$7M in free cash flow** **[933974_1926440:1]**, while diluted EPS for continuing operations was **($0.40)**, highlighting operational challenges **[933974_0001437749-25-014901_ex_779225.htm:0]**.
- Full-year fiscal 2025 guidance was reiterated with expectations of **3%-5% organic revenue growth** and an anticipated **300 basis points expansion in adjusted EBITDA margin** **[933974_20250507NE81708:0]** **[933974_20250507NE81708:1]**.
- A robust balance sheet with **$540M in cash** and no outstanding debt positions Azenta for long-term investments amid an evolving macroeconomic environment **[933974_1926440:1]** **[933974_0001437749-25-014901_ex_779225.htm:0]** **[933974_0001437749-25-014901_ex_779225.htm:1]**.

Azenta Inc Reports Q2 Fiscal 2025 Earnings & Guidance Update

ef2899d3d14212310bc3617e188fbbad9fad14a2c7a5c91fbf96d139c3a750b8

- **Revenue reached $143M** in Q2 2025, showing a **5% YoY increase** and **6% organic growth**, driven by strong performance in key segments.  **[933974_1926440:1]**   
- **Non-GAAP EPS was $0.05** with an **adjusted EBITDA margin of 10.0%** and **$7M in free cash flow**, reflecting improved profitability.  **[933974_1926440:1]**   
- The **SMS segment generated $80M** in revenue and the **Multiomics segment $64M**, both contributing to robust top-line growth.  **[933974_1926440:1]**   
- The balance sheet remains strong with **$540M in cash** and no outstanding debt, positioning Azenta for long-term investments.  **[933974_1926440:1]** **[933974_1926440:2]** **[933974_1926440:3]**

Azenta Inc Reports Q2 2025 Earnings Results

aa079623ca652df0dee03a26e63b0eebe85b9a5ad11ae78aa04f3a8e099a1f82

758cda67f4a2264a7adb182db161d81c808557cb8539e6d6047ec3e3d0cfe61e

003486eea41b7efec98ec634fdca069e096958074b496cfd2d553d8e6cb9be49

Revenue (Products) [USD, thousands]

Revenue (Services) [USD, thousands]

Total revenue [USD, thousands]

Cost of revenue (Products) [USD, thousands]

Cost of revenue (Services) [USD, thousands]

Total cost of revenue [USD, thousands]

Gross profit [USD, thousands]

Operating expenses (Research and development) [USD, thousands]

Operating expenses (Selling, general and administrative) [USD, thousands]

Impairment of intangible assets [USD, thousands]

Operating expenses (Contingent consideration - fair value adjustments) [USD, thousands]

Restructuring charges [USD, thousands]

Total operating expenses [USD, thousands]

Operating loss [USD, thousands]

Other income (Interest income, net) [USD, thousands]

Other income (Other income (expense), net) [USD, thousands]

Loss before income taxes [USD, thousands]

Income tax (benefit) expense [USD, thousands]

Loss from continuing operations [USD, thousands]

Income (loss) from discontinued operations, net of tax [USD, thousands]

Net loss [USD, thousands]

Basic net loss per share (Loss from continuing operations) [USD]

Basic net loss per share (Income (loss) from discontinued operations, net of tax) [USD]

Basic net loss per share [USD]

Diluted net loss per share (Loss from continuing operations) [USD]

Diluted net loss per share (Income (loss) from discontinued operations, net of tax) [USD]

Diluted net loss per share [USD]

Weighted average shares used in computing net loss per share (Basic) [shares, thousands]

Weighted average shares used in computing net loss per share (Diluted) [shares, thousands]

28fb0bf5dca00c542a9e250051a52e1dff2cf06eeb56f8971a0d261cb582fec4

902db67b8b66c228339b71fb93110777307541c8c6f685e1168e699b39c1ca3a

- **Revenue from continuing operations reached $143M**, marking a **5%** year-over-year increase driven by Sample Management Solutions ($80M, up 8%) and Multiomics ($64M, up 2%) **[933974_0001437749-25-014901_ex_779225.htm:0]** **[933974_20250507NE81708:0]**.
- The company posted a **diluted EPS of ($0.40)** for continuing operations, with operating loss and margin details highlighting operational challenges **[933974_0001437749-25-014901_ex_779225.htm:0]** **[933974_20250507NE81708:0]** **[933974_20250507NE81708:1]**.
- **Guidance** for full-year fiscal 2025 was reiterated, with organic revenue expected to grow **3% to 5%** and adjusted EBITDA margin anticipated to expand by approximately **300 basis points** **[933974_20250507NE81708:0]** **[933974_20250507NE81708:1]**.
- Management emphasized a robust cash position and a disciplined approach amid an evolving macroeconomic environment **[933974_0001437749-25-014901_ex_779225.htm:0]** **[933974_0001437749-25-014901_ex_779225.htm:1]**.

Azenta Reports Q2 Fiscal 2025 Results

c09f1e23919720f42e80c3c3008f8909fb208d5226b4af36b918f875632fb6b7

- **Revenue from continuing operations reached $143M**, marking a 5% year-over-year increase driven by stronger performance in **Sample Management Solutions** ($80M, up 8%) and **Multiomics** ($64M, up 2%).  **[933974_0001437749-25-014901_ex_779225.htm:0]** 
- The quarter reported a **diluted EPS of ($0.40)** from continuing operations with management emphasizing a robust cash position and a disciplined approach amid an evolving macroeconomic environment.  **[933974_0001437749-25-014901_ex_779225.htm:0]** **[933974_0001437749-25-014901_ex_779225.htm:1]**

Azenta Reports Q2 2025 Financial Results

4fa3f9be24dbb085d9948f660e17f0ee13431b7efaea84955b292a6fcb8115c7

- **Azenta** reported Q2 fiscal 2025 revenue from continuing operations of **$143 million**, reflecting a **5%** year-over-year increase, with its Sample Management Solutions and Multiomics segments driving this growth.  **[933974_20250507NE81708:0]**   
- The company posted a diluted EPS of **($0.40)** for continuing operations, with operating loss and margin details highlighting operational challenges despite a strong cash position.  **[933974_20250507NE81708:0]** **[933974_20250507NE81708:1]**   
- **Guidance** for full-year fiscal 2025 was reiterated, with organic revenue expected to grow **3% to 5%** and adjusted EBITDA margin anticipated to expand by approximately **300 basis points**.  **[933974_20250507NE81708:0]** **[933974_20250507NE81708:1]**

ca4dac0e9cda9818b73ff1365ec0481f21c3d09a8e0510a221b4088c9e94b61a

c6f47d69980538766aaf33172703fa5ef3fd755b193300da9a1b009ea2c3db88

2f537efe5ea0565cb7b2d51944089da3bfb36916b1671dc55f727a099a4b3520

4046bf3c26c71000c38d0565c0c5f91932eeeefee62a9b66db64f80611c9698c

17a85bedb197ab77a8c5152bf2ff2280d74144b4011654b7174b1827727dfba7

31ae23d1f33766233312d64a3f5426ade794e47d9fb1a7d37fb440708a91353e

7f5a94a1e18797187c6503bbc96402ef8df80b5fbd7329f911dd77311da9c72e

e35df963c1b61c9ca8312e96a3a7931d2c611f3c02399832423eeb0a44ef3f01

fc16962bf8b37f17d006e8e95cca5f07938e5477ce645c4e7f6d236fabb99b47

dcfd187819ac52d3523c5513b05a06d68687307058e28642b5784b37674556e9

87ad6cef2ecd025fadd47bbaa1b07faa427cfc621a5a8402abc6f37a6546d28f

- Azenta is experiencing strong growth in its cell and gene therapy business, with their auto cryo business increasing by **67% last year**, and continued positive trends this year.  **[AZTA_3414416_14]**
- The company demonstrated strong performance in its Multiomics segment, with Next-Generation Sequencing (NGS) revenue growing **11%** in the quarter, indicating positive momentum.  **[AZTA_3414416_8]**
- Azenta has strong revenue visibility with **75% of 2025 revenue secured**, indicating a robust pipeline and backlog in their Sample Management Solutions business.  **[AZTA_3414416_11]**

bb132ee4880a50d31a1c03781dbe05a2ced086bb01bf2d2559a041956155a8ed

1. **Illumina China Impact**  
   **Q:** Any impact from Illumina being added to China's unreliable entity list?  
   **A:** Management stated that they anticipate minimal risk from Illumina being added to China's unreliable entity list.  **[AZTA_3414416_7]**  Their NGS business in China does not own Illumina products like NovaSeq. Instead, they primarily partner with BGI in China and run both Illumina and MGI platforms.  **[AZTA_3414416_7]**  The revenue from NGS in China is roughly **7% to 10% of Multiomics**, and they see no material risk due to the Illumina issue.  **[AZTA_3414416_7]** 

2. **Margin Outlook**  
   **Q:** Will margins plateau in the back half, and what's driving that?  
   **A:** Management reported **Q1 EBITDA of 9%**, and over **10%** when excluding one-time events.  **[AZTA_3414416_9]**  They anticipate a pathway towards **300 basis points** improvement in margins. They are confident in their guidance based on actions taken this quarter and planned initiatives in the second and third quarters.  **[AZTA_3414416_9]** 

3. **Multiomics Guidance Deceleration**  
   **Q:** What's causing the implied deceleration in Multiomics growth?  
   **A:** Management emphasized that they are focusing on the full year and are holding their guidance despite a strong quarter where NGS was up **11%**.  **[AZTA_3414416_8]**  They attribute any apparent deceleration to timing issues and significant changes happening within the company.  **[AZTA_3414416_8]** 

4. **Tariff Impact Exposure**  
   **Q:** Any risks related to tariffs on China, Mexico, or Canada?  
   **A:** Management believes the impact of increased tariffs on China is immaterial, estimating a potential incremental cost of **$1 million to $2 million** at most, which is already factored into their guidance.  **[AZTA_3414416_10]**  They have minimal risk related to Mexico and Canada.  **[AZTA_3414416_10]** 

5. **B Medical Divestiture Timing**  
   **Q:** Is the B Medical sale taking longer than expected?  
   **A:** Management confirmed that they are focused on maximizing the value of the B Medical sale and that the process is ongoing with active involvement from the Board's value creation committee.  **[AZTA_3414416_9]**  They are pleasantly surprised by the number of interested parties.  **[AZTA_3414416_9]** 

6. **Share Buyback and M&A Strategy**  
   **Q:** Is there still a share buyback program, and will you consider M&A?  
   **A:** Management is prioritizing capital allocation towards gross margin improvement, growth initiatives in R&D, and potential M&A before considering share buybacks.  **[AZTA_3414416_15]**  They believe there are more opportunities in these areas and do not view share repurchases as a priority at this time.  **[AZTA_3414416_15]** 

7. **Sample Management Solutions Timing**  
   **Q:** Was the slow start in SMS due to timing or customer caution?  
   **A:** Management attributed the slow start in SMS to timing issues, noting that large stores were down **13%** in Q1 but have a robust pipeline with **75%** of 2025 revenue secured.  **[AZTA_3414416_11]**  They are confident in the back half of the year and see strong demand in Consumables and Instruments, up **9%** in the quarter.  **[AZTA_3414416_11]** 

8. **Post-COVID ULT Capacity Impact**  
   **Q:** Are you affected by the post-COVID overcapacity in ultra-cold storage?  
   **A:** Management believes they are not impacted by the ULT glut as their stores are sophisticated asset management units for pharma and biotech, focusing on compound management, sample management, and antibodies.  **[AZTA_3414416_16]**  They are not seeing overlap with standard ULT freezers and have been growing well over the ULT glut.  **[AZTA_3414416_16]** 

9. **Gene Synthesis Capacity Plans**  
   **Q:** How are you addressing Gene Synthesis capacity and China tariffs?  
   **A:** Management stated that their Gene Synthesis business is a mid-single-digit grower, serving biotech and pharma customers with complex, long reads.  **[AZTA_3414416_18]**  They are cautious about capacity expansion and will not rush decisions until they have clarity. They feel comfortable with the business despite China tariffs.  **[AZTA_3414416_18]** 

10. **Sanger Sequencing Shift and Pricing**  
    **Q:** Are there pricing pressures in Multiomics beyond NGS?  
    **A:** Management observed price stability in NGS with **11%** growth but noted challenges in Sanger sequencing due to a technology shift, leading to an **11%** decline.  **[AZTA_3414416_17]**  However, they are seeing significant growth in Plasmid-EZ technology, up nearly **300%** year-over-year.  **[AZTA_3414416_17]** 

11. **Academic and Government Exposure**  
    **Q:** Any impact from NIH funding uncertainties?  
    **A:** Management's end market exposure includes **16%** academic and **15%** medical government sectors.  **[AZTA_3414416_13]**  They have seen some project delays in government-funded areas but believe these will resume once funding decisions are made. They can adjust focus to pharma and biotech if needed.  **[AZTA_3414416_13]** 

12. **Cell and Gene Therapy Progress**  
    **Q:** What progress are you seeing in cell and gene therapy?  
    **A:** Management reported that their auto cryo business increased by **67%** last year and they delivered **11 units** this quarter.  **[AZTA_3414416_14]**  They are bullish on the cell and gene therapy market and see the positive trend continuing.  **[AZTA_3414416_14]** 

13. **BioArc Ultra Opportunity**  
    **Q:** Can you frame the BioArc Ultra opportunity and revenue timing?  
    **A:** Management confirmed that the BioArc Ultra project in the U.K. was included in guidance and is a continuation of their partnership with the bio center, involving multimillion-dollar, highly customized solutions.  **[AZTA_3414416_6]**  They expect the bio center to be operational in early **2026**.  **[AZTA_3414416_6]** 

cc3c7dca7ae14ddc292e95c8ad8c5f46f5adf3b7fb54ba37ebd05bdaf0cdf62c

- The **Sanger sequencing business declined by 11% year-over-year** due to a **shift in technology**, and it faces challenges that may not be fully offset by growth in new products like Plasmid-EZ, potentially impacting future revenues.  **[AZTA_3414416_17]**
- **Large store revenues in the Sample Management Solutions segment decreased by 13% in the first quarter**, indicating potential challenges or delays in this business line, which may affect overall performance if not resolved.  **[AZTA_3414416_11]**
- The company's guidance for the Multiomics segment implies a **deceleration in growth in the latter half of the year**, raising concerns about future growth prospects and the sustainability of recent positive trends.  **[AZTA_3414416_8]**

7511172771a7debe8f5ce041c37960846f92f2b2574e43b9755afdfac3c9118a

7296ffe9e9c95af436d14b3de1f98fe3ae34b5ffc8a2243435dcd8684000ca39

1. **Guidance and Targets Achievability**  
   **Q:** Are fiscal '26 targets achievable excluding B Medical?  
   **A:** Management believes the fiscal '26 targets, including **15‒17% EBITDA margin**, are achievable even after excluding B Medical. The guidance of **3‒5%** organic growth for fiscal '25 accounts for the current market environment, and if recovery comes in the second half of 2025, there could be upside.  **[AZTA_3408010_7]** 

2. **EBITDA Margin Outlook**  
   **Q:** Is the fiscal '25 EBITDA margin guidance flattish due to B Medical exit?  
   **A:** While recent quarters showed EBITDA margins above **10%**, management is guiding conservatively due to necessary investments in fiscal '25. They expect **300 basis points** of EBITDA margin expansion each year and remain confident in achieving the **15‒17% EBITDA margin** target by fiscal '26.  **[AZTA_3408010_8]** 

3. **B Medical Divestiture Timing**  
   **Q:** When will the B Medical transaction close?  
   **A:** Management expects the B Medical divestiture to close in the **first half** of the year, certainly within one year, allowing focus on high-margin businesses.  **[AZTA_3408010_19]** 

4. **China Performance and Tariff Impact**  
   **Q:** How did China perform, and are tariffs a concern?  
   **A:** China revenue grew **10%** in Q4 and **12%** for fiscal '24. Management does not anticipate tariff impacts, as they manufacture regionally—serving China from China and the U.S. from the U.S.  **[AZTA_3408010_10]** 

5. **NGS Growth and Pricing Trends**  
   **Q:** What are the trends in NGS pricing and volume?  
   **A:** NGS revenues grew **25%** in the quarter, driven by increased volume and price stabilization from Q3 to Q4. Management remains cautious on pricing trends but notes positive momentum entering fiscal '25.  **[AZTA_3408010_9]** **[AZTA_3408010_13]** 

6. **Stores Business Outlook**  
   **Q:** Why were stores down, and what's the outlook?  
   **A:** Stores were down due to a tough comparison with a record growth quarter in fiscal '23. With **75%** visibility into the backlog, management is confident in their fiscal '25 guidance. They see a market shift toward automated storage solutions and are bullish on their capabilities.  **[AZTA_3408010_12]** 

7. **Capital Allocation and M&A Strategy**  
   **Q:** What's the M&A strategy and capital allocation focus?  
   **A:** The company emphasizes portfolio optimization, operational excellence, and disciplined capital allocation. M&A targets must meet stringent **double-digit ROIC** criteria. They're interested in strategic tuck-ins, especially in the SMS business and biorepositories, aiming to enhance automation and margins.  **[AZTA_3408010_11]** **[AZTA_3408010_17]** 

8. **CapEx Expectations Post-Divestiture**  
   **Q:** Will CapEx trend lower after B Medical sale?  
   **A:** CapEx may decrease but is expected to remain within **4–6%** of sales. Management is reviewing capital deployment to align with strategic initiatives, focusing on productivity and growth opportunities.  **[AZTA_3408010_20]** 

9. **EBITDA Margin Expansion Basis**  
   **Q:** Is the 300 bps margin expansion on an apples-to-apples basis?  
   **A:** Yes, the **300 basis points** of EBITDA margin expansion is calculated on a comparable basis for the remaining company after B Medical's divestiture. Recast financials will be provided for clarity.  **[AZTA_3408010_15]** **[AZTA_3408010_16]** 

10. **Pricing Headwinds in NGS**  
    **Q:** Are pricing headwinds in NGS expected to continue?  
    **A:** Management anticipates continued pricing headwinds in NGS for 2025 but is cautious about declaring a trend after one quarter of price stabilization.  **[AZTA_3408010_18]** 

d38c82292eb0d74a0d8bcf9d1423a372f3edcc923f68e3da64e1b8e6f1f6417b

- **Strong Growth in Next-Generation Sequencing (NGS) Segment**: Azenta's NGS business grew **25% year-over-year** in the fourth quarter, driven by increased volumes and price stabilization. This robust growth indicates positive momentum heading into fiscal year 2025.  **[AZTA_3408010_9]** ,  **[AZTA_3408010_13]**
- **Margin Expansion with Confidence in Achieving Long-Term Targets**: The company achieved **300 basis points of adjusted EBITDA margin expansion** in fiscal year 2024, resulting in margins above **11%**. Azenta is confident in achieving an EBITDA margin of **15% to 17% by fiscal year 2026**, highlighting strong operational efficiencies and cost optimization initiatives.  **[AZTA_3408010_16]** ,  **[AZTA_3408010_7]**
- **Competitive Advantage in Automated Storage Solutions**: Despite a decline in stores revenue due to tough comparables, Azenta has **75% visibility into the backlog** for its storage business and is bullish on the shift towards automated storage solutions. The company believes it has **unique capabilities and competitive advantages** in this high-growth area, which could drive significant future growth.  **[AZTA_3408010_12]**

d6135efcfe168bfb0c3013cce743e0b0a178c5cd4b61fedb29942018040b6eb8

- Azenta's **guidance for fiscal year 2025 is 3% to 5% organic revenue growth**, which is **lower than previous expectations**. Management acknowledges that they have **"struggled on the top line"** and there is **uncertainty in the market**, indicating potential challenges in achieving growth targets.  **[AZTA_3408010_7]**
- The company is experiencing **sales force turnover and open territories**, with potential for **distraction due to ongoing transformation efforts**, which could impact execution and sales performance.  **[AZTA_3408010_14]**
- While **Next-Generation Sequencing (NGS) grew 25% in the quarter**, management is cautious about the sustainability of this growth, stating **"We don't want to count on that trend right now as continuing"**, suggesting that future NGS growth may not match recent strong performance.  **[AZTA_3408010_9]**

8f4af4051aad0cd1b0900b5a17fcc42012c7cc50cb10e6ec9266d67731bd085b

Current Assets (USD, thousands)

Cash and Cash Equivalents (USD, thousands)

Accounts Receivable (USD, thousands)

Inventory (USD, thousands)

Non-Current Assets (USD, thousands)

Property, Plant, and Equipment (PP&E) (USD, thousands)

Goodwill (USD, thousands)

Intangible Assets (USD, thousands)

Current Liabilities (USD, thousands)

Accounts Payable (USD, thousands)

Short-term Debt (USD, thousands)

Accrued Expenses (USD, thousands)

Non-Current Liabilities (USD, thousands)

Long-term Debt (USD, thousands)

Lease Liabilities (USD, thousands)

Deferred Tax Liabilities (USD, thousands)

Shareholders' Equity (USD, thousands)

Retained Earnings (USD, thousands)

Common Stock (USD, thousands)

Additional Paid-in Capital (USD, thousands)

af240cc22dd814924aced2d57a917db976500f0f0c2b9a098c83b62d0cb492c9

670c263308c9afcbfff5aa0c6b1c5c55d2b5f08308b6d64f156490c897d1c487

ff858ec601915d259d8d8d517eca44b7a2f4a45cd7a66844aa919c3b529a92ed

United States

Africa

China

United Kingdom

Rest of Europe

Asia Pacific/Other

Total Revenue

fd0fce201f2f06adc132a09ec9a111cd918759cabe1c61da220a4327fa787cbe

- **Strong growth in Next Generation Sequencing (NGS) services**, with over **700 new customers** added this quarter—a **100 increase from the prior quarter**—indicating significant momentum in customer acquisition and outsourcing of NGS work to Azenta due to cost advantages and capacity.  **[AZTA_3396799_11]**  Volume continues to grow, with **20% growth in number of samples processed** for the fifth consecutive quarter  **[AZTA_3396799_11]** **[AZTA_3396799_15]** .
- **Cryogenic freezer revenue increased by almost 40%**, driven by heightened demand for **automated cryogenic storage systems** and multiple system orders, reflecting customer adoption of Azenta's automated solutions and a trend towards automation in sample management  **[AZTA_3396799_1]** **[AZTA_3396799_7]** .
- The **ASCEND 2026 transformation program** is delivering cost savings earlier than expected, with the **closure of 10 sites and optimization of another 3**, contributing to margin expansion. Despite a lower revenue guide, Azenta expects to achieve **approximately 300 basis points of margin expansion** for fiscal year 2024, demonstrating strong operational execution and commitment to profitability  **[AZTA_3396799_6]** **[AZTA_3396799_12]** .

95e2114a27b20ff85e276eab21cd05f2cea81f127897818538587d7b90a54202

1. **NGS Business Outlook**  
   **Q:** Why is outsourcing NGS demand increasing now?  
   **A:** Customers are delaying their own sequencing tool purchases and outsourcing to us, resulting in over **700 new customers** this quarter, an increase of **100** from the prior quarter.  **[AZTA_3396799_11]**  Record quote activity and stabilized pricing indicate that customers are leveraging our cost structure for reduced prices and outsourcing more NGS work.  **[AZTA_3396799_11]**  Volume continues to grow, marking the fifth consecutive quarter of **20% quarter-over-quarter growth**.  **[AZTA_3396799_11]** 

2. **Margin Expansion Drivers**  
   **Q:** What's driving margin expansion despite lower revenue?  
   **A:** The ASCEND 2026 program is yielding results faster than anticipated, with actions like optimizing or closing **10 sites** and rightsizing **3 others**, contributing to margin improvements.  **[AZTA_3396799_12]**  Cost initiatives related to ASCEND 2026 are helping us reach targets, and we remain confident in our fiscal year '26 commitment.  **[AZTA_3396799_12]** 

3. **NGS Volume vs. Revenue Growth**  
   **Q:** Is NGS volume growth a proxy for future revenue?  
   **A:** With NGS volumes up **20%**, and pricing pressures stabilizing, we are optimistic that future revenue will reflect volume growth.  **[AZTA_3396799_15]**  Customer behavior suggests more outsourcing, and strong customer activity supports continued progress.  **[AZTA_3396799_15]** 

4. **B Medical Resource Allocation**  
   **Q:** How are you managing B Medical amid revenue variability?  
   **A:** We aim to build B Medical into an accretive EBITDA margin business for the long term.  **[AZTA_3396799_8]**  Despite revenues being down **29%** this year, the business achieved above overall EBITDA margin this quarter.  **[AZTA_3396799_8]**  Efforts around Ascend 2026 to rightsize the business are starting to bear fruit, providing the runway to explore opportunities profitably.  **[AZTA_3396799_8]** 

5. **C&I Growth and Guidance Changes**  
   **Q:** What are you seeing in C&I markets, and is guidance change timing-related?  
   **A:** C&I grew **17%** in the third quarter.  **[AZTA_3396799_10]**  While instrument bookings were soft due to capital spending constraints, the strong pipeline indicates healthy demand tied to spending delays.  **[AZTA_3396799_10]**  Consumables saw significant double-digit sequential and year-over-year revenue increases.  **[AZTA_3396799_10]**  The guidance change is purely timing-related, with a **$5 million** shift in B Medical revenue and another **$5 million** in OEM product line revenue moving to Q1 of '25.  **[AZTA_3396799_10]** 

6. **Cryogenic Freezers Growth**  
   **Q:** What drove 40% growth in cryogenic freezers?  
   **A:** Growth was driven by automated systems, with multiple system orders from customers transitioning to automation.  **[AZTA_3396799_7]**  These systems are priced between **$150,000 to $250,000**, and we haven't seen reluctance from customers to purchase.  **[AZTA_3396799_7]**  The trend favors automated systems over manual cryogenic freezers.  **[AZTA_3396799_7]** 

7. **Multiomics Revenue and NovaSeq X Plus Transition**  
   **Q:** Has the NovaSeq X Plus transition finished, and is revenue increasing?  
   **A:** The transition to the NovaSeq X Plus is complete, with almost all data now generated on the X Plus tool.  **[AZTA_3396799_14]**  While price reductions are offset by volume gains, we've maintained margins due to lower raw material and labor costs, and leveraging fixed overhead.  **[AZTA_3396799_14]**  NGS revenue grew **3%** this quarter, the largest growth in the past year, signaling a positive trend.  **[AZTA_3396799_14]** 

8. **EBITDA Margin Guidance**  
   **Q:** What factors contribute to the implied EBITDA margin step-up into Q4?  
   **A:** We don't anticipate a margin step-up from Q3 to Q4; margins may be flat to slightly down.  **[AZTA_3396799_9]**  Hitting the overall guidance doesn't require a sequential margin increase.  **[AZTA_3396799_9]** 

9. **Site Closures**  
   **Q:** Any further site closures expected?  
   **A:** We are working on a couple more site closures but haven't disclosed whether they'll occur in Q4 or next year.  **[AZTA_3396799_13]** 

10. **Synthesis Manufacturing in the U.S.**  
    **Q:** Have customers requested U.S. manufacturing for synthesis?  
    **A:** Customers have inquired from a risk mitigation standpoint, and we are prepared, with existing synthesis manufacturing in North America.  **[AZTA_3396799_16]**  There's no push for it, and no customers have left due to our current structure.  **[AZTA_3396799_16]** 

237ef988b2369fb201737d48d51d94aede2bb8e004ca8f3ef01f2318722ef9d5

1. Your guidance for the Multiomics segment remains at low single-digit growth despite achieving 11% growth in NGS this quarter; what factors are causing you to anticipate a deceleration in growth for the remainder of the year?
2. Despite your confidence in the SMS backlog and pipeline, large stores revenue was down 13% this quarter; is this decline purely due to timing, or are you observing underlying customer cautiousness that could impact your mid-single-digit growth guidance for SMS?
3. Given the 11% year-over-year decline in Sanger Sequencing revenue due to shifts in sequencing technology, how do you plan to address these headwinds and offset the declines within the Multiomics segment?
4. With the sale process of B Medical Systems still in the initial stages, how might this extended timeline affect your strategic initiatives and capital allocation priorities, and what steps are you taking to ensure it doesn't hinder value creation?
5. You have undertaken restructuring to rightsize your G&A cost structure and improve margins; can you provide more details on the expected cost savings, any associated one-time charges, and how these changes might impact your ability to invest in growth initiatives?

4dcea10ef28fcc63834ead97476d8860f8a9ee859fe2dcd7429345f510d30c2d

- **Revenue Guidance Lowered Due to Order Shifts and Delays**: The company has lowered its full-year revenue guidance due to the shifting of OEM product orders from the second half of 2024 into Q1 of 2025 and delays in converting B Medical's pipeline into firm orders. This results in approximately $5 million of revenue moving from fiscal year 2024 to 2025, impacting their Sample Management Solutions (SMS) segment.  **[AZTA_3396799_6]** ,  **[AZTA_3396799_10]**
- **Pricing Pressure in Next Generation Sequencing (NGS) Limiting Revenue Growth**: Despite over 20% growth in NGS volume, revenue growth is only 3% due to significant price reductions in sequencing services. This indicates ongoing pricing headwinds in the NGS market, which may continue to pressure margins despite increased volumes.  **[AZTA_3396799_15]** ,  **[AZTA_3396799_11]**
- **Dependence on Cost-Cutting Measures for Margin Expansion**: Margin improvements are largely driven by cost-cutting initiatives under the ASCEND 2026 program, including site closures and operational optimizations. While these measures enhance short-term profitability, they may signal challenges in achieving organic growth and could affect future operational capacity.  **[AZTA_3396799_13]**

1f713dd33cd019e4f26055c8aa3031e4c6ede9f165e9e1e894eb5b47b7e27707

| Name                | Is Executive | Is Board Member | Position                                      | External Roles                                                                                     | Short Bio                                                                                                                                                                                                                     | Start Date       |
|---------------------|--------------|------------------|----------------------------------------------|----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| John P. Marotta     | True         | False            | President and Chief Executive Officer (CEO)  | None                                                                                               | Extensive experience in life sciences and healthcare; previously CEO of PHC Holdings Corporation; joined Azenta in 2024.                                                              | September 9, 2024.  **[0001437749-24-028399_azta20240904_8k.htm:1]** **[0001437749-24-028399_ex_721159.htm:0]** **[20240904NE97187:0]**  |
| Lawrence Lin        | True         | False            | Executive Vice President and Chief Financial Officer (CFO) | None                                                                                               | Finance leader with expertise in business systems and lean principles; previously CFO at GeoStabilization International LLC.                                                          | November 13, 2024.  **[0001437749-24-034563_ex_746625.htm:0]** **[0001437749-24-034563_azta20240708_8k.htm:2]**  |
| Jason W. Joseph     | True         | False            | Senior Vice President, General Counsel, and Secretary | None                                                                                               | Oversees legal affairs, corporate governance, and compliance; joined Azenta in 2011 and promoted to SVP in 2017.                                                                       | March 2011.  **[0001140361-23-057904_ny20014789x1_def14a.htm:39]** **[0001140361-22-046510_ny20005618x1_def14a.htm:40]**  |
| Olga Pirogova       | True         | False            | Senior Vice President and Chief Human Resources Officer (CHRO) | None                                                                                               | Leads HR strategy; previously CHRO at Speedcast and held leadership roles at BD (Becton, Dickinson & Company).                                                                         | August 2023.  **[0001140361-23-057904_ny20014789x1_def14a.htm:37]**  |
| David Wang          | True         | False            | Senior Vice President and General Manager, Sample Management Solutions (SMS) | None                                                                                               | Leads SMS business; previously held roles at McKinsey, Johnson & Johnson, and PerkinElmer.                                                                                            | December 2022.  **[0001140361-24-049734_ny20038035x1_def14a.htm:36]** **[0001140361-23-057904_ny20014789x1_def14a.htm:36]**  |
| Dr. Ginger Zhou     | True         | False            | Senior Vice President and General Manager, Multiomics | None                                                                                               | Leads Multiomics business; joined Azenta in 2018 and has a Ph.D. in Molecular Biology and Biochemistry.                                                                                | November 2018.  **[0001140361-24-049734_ny20038035x1_def14a.htm:36]** **[0001140361-23-057904_ny20014789x1_def14a.htm:40]**  |
| Violetta Hughes     | True         | False            | Vice President, Chief Accounting Officer, and Principal Accounting Officer | None                                                                                               | Oversees financial accounting and reporting; previously SVP and CAO at Akebia Therapeutics.                                                                                           | August 2023.  **[0001140361-24-049734_ny20038035x1_def14a.htm:36]** **[0001140361-23-057904_ny20014789x1_def14a.htm:36]**  |
| Frank E. Casal      | False        | True             | Chair of the Board of Directors              | None                                                                                               | Former Vice Chair of Audit at KPMG LLP; joined Azenta's Board in 2021 and became Chair in 2024.                                                                                        | November 2021.  **[0001140361-24-049734_ny20038035x1_def14a.htm:27]** **[0001140361-23-057904_ny20014789x1_def14a.htm:25]**  |
| William L. Cornog   | False        | True             | Director and Chair of the Value Creation Committee | Board Member at Brightview Holdings Inc. (NYSE: BV) and LiveWire (NYSE: LVWR)                     | Former head of KKR Capstone; expertise in portfolio management and value creation.                                                                                                     | November 2024.  **[20241104NE47240:1]** **[0001437749-24-033059_ex_742001.htm:1]**  |
| Alan J. Malus       | False        | True             | Director                                      | None                                                                                               | Former Corporate EVP at Thermo Fisher; extensive experience in life sciences and diagnostics.                                                                                         | November 2024.  **[0001140361-24-049734_ny20038035x1_def14a.htm:30]**  |
| Erica J. McLaughlin | False        | True             | Director and Chair of the ESG Committee      | EVP, CFO, and Head of Corporate Strategy at Cabot Corporation; Member of FM Global New York Advisory Board | Financial expert with experience in ESG, mergers, and acquisitions; CFO at Cabot Corporation.                                                                                         | April 2020.  **[0001140361-23-057904_ny20014789x1_def14a.htm:27]** **[0001140361-24-049734_ny20038035x1_def14a.htm:3]**  |
| Dr. Martin Madaus   | False        | True             | Director                                      | Board Member at Repligen Corporation, Quanterix Corporation, and Standard BioTools Inc.; Senior Operating Executive at The Carlyle Group | Former CEO of Millipore Corporation; expertise in life sciences and diagnostics.                                                                                                       | January 2024.  **[0001140361-24-049734_ny20038035x1_def14a.htm:29]** **[0001140361-23-057904_ny20014789x1_def14a.htm:33]**  |
| Robyn C. Davis      | False        | True             | Director and Chair of the Finance Committee  | Corporate Director at Psychemedics Corporation (NASDAQ: PMD); Director at Akston Biosciences, LLC | Managing Director of AngelHealthcare Investors; expertise in growth strategy and leadership development.                                                                               | June 2013.  **[0001140361-23-057904_ny20014789x1_def14a.htm:26]** **[0001140361-24-049734_ny20038035x1_def14a.htm:28]**  |
| Didier Hirsch       | False        | True             | Nominee for Director and Chair of the Audit Committee | Board Member at Knowles Corporation and Sophia Genetics SA                                        | Former CFO of Agilent Technologies; expertise in financial management and governance.                                                                                                  | Pending Election.  **[0001558370-23-018844_azta-20231113xex99d2.htm:1]** **[0001140361-23-057904_ny20014789x1_def14a.htm:32]**  |
| Tina S. Nova        | False        | True             | Director                                      | Director at Exagen, Inc. (NASDAQ: XGN)                                                            | Industry veteran in life sciences; expertise in IPOs, mergers, and acquisitions.                                                                                                       | January 2023.  **[0001140361-24-049734_ny20038035x1_def14a.htm:31]** **[0001140361-23-057904_ny20014789x1_def14a.htm:28]**  |
| Michael Rosenblatt  | False        | True             | Director                                      | Director at Rubius Therapeutics; Senior Advisor at Flagship Pioneering and Bain Capital Life Sciences | Former EVP and CMO at Merck; extensive experience in healthcare and life sciences.                                                                                                     | September 2018.  **[0001140361-23-057904_ny20014789x1_def14a.htm:29]** **[0001140361-22-046510_ny20005618x1_def14a.htm:30]**  |
| Quentin Koffey      | False        | True             | Director                                      | Founder and Managing Partner at Politan Capital Management; Director at Masimo Corporation (NASDAQ: MASI) | Investment expert with a focus on capital allocation and governance; founder of Politan Capital Management.                                                                             | November 2024.  **[20241104NE47240:1]** **[0001437749-24-033059_ex_742001.htm:1]**  |

c006f8c7c38bf83a145d91c98554697bb8fed1c6041a2f49d5d36904880cadba

Total Revenue (USD, thousands)

Cost of Goods Sold (COGS) (USD, thousands)

SG&A (USD, thousands)

R&D (USD, thousands)

D&A (USD, thousands)

Interest Expense (USD, thousands)

Operating Income (EBIT) (USD, thousands)

Net Income (USD, thousands)

EPS - Basic (USD)

EPS - Diluted (USD)

23957e9a749f990f9378817ec8b1f9cd4ed8b4f98d4e7802a3dc417392b08102

505d7111da5381e77b80c6160e4eade688a72a31e884e05e4ff364cd991f9cd7

1. **B Medical Guidance Reduction**  
   **Q:** Why is B Medical guidance being lowered?  
   **A:** B Medical's guidance is lowered due to uncertainty in the **$60 million DRC contract** timing and the exit from the U.S. non-vaccine cold chain (non-VCC) market.  **[AZTA_3387389_10]**  These factors are key contributors to the reduction.  **[AZTA_3387389_10]** 

2. **EPS Guidance Increase Despite Lower Revenue**  
   **Q:** How is EPS guidance raised despite lowered revenues?  
   **A:** The EPS guidance increased by **$0.08** due to expected **$20 million** revenue step-up from Q3 to Q4 and progress on cost reduction initiatives like site exits and organizational simplification.  **[AZTA_3387389_16]**  Gross profit improvements and the Ascend 2026 program contribute to confidence in meeting EBITDA and EPS targets.  **[AZTA_3387389_16]** 

3. **Sample Management Revenue Timing**  
   **Q:** Is Sample Management growth expected to accelerate in Q4?  
   **A:** Yes, a **$2 million** order in Sample Management was pushed from Q3 to Q4 due to minor supply chain delays.  **[AZTA_3387389_14]**  This will result in a revenue step-up from Q3 to Q4, with low single-digit growth in Q3 and higher growth in Q4.  **[AZTA_3387389_14]** 

4. **Large Stores Revenue Growth**  
   **Q:** How is the large stores business performing?  
   **A:** Large stores revenue grew **50% year-over-year** in the quarter, and the backlog continues to grow even as revenue increases.  **[AZTA_3387389_11]**  There's high interest in large automated stores, and the BioArc Ultra launch is contributing positively.  **[AZTA_3387389_11]** 

5. **NGS Transition Impact**  
   **Q:** What's the status of the NGS transition and its impact?  
   **A:** The shift to NovaSeq X Plus is ongoing, causing a short-term dip as volumes ramp up.  **[AZTA_3387389_15]**  Despite this, gross margins are holding or improving, and the company is ahead of prior transitions.  **[AZTA_3387389_15]** 

6. **Multiomics Growth in China**  
   **Q:** What's driving Multiomics growth in China?  
   **A:** Multiomics in China has seen **double-digit growth** for four consecutive quarters despite market downturns.  **[AZTA_3387389_19]**  Success is due to strong local presence, aggressive sales teams, and increased capacity, including a new facility in Suzhou.  **[AZTA_3387389_19]** 

7. **CEO Retirement and Succession**  
   **Q:** What is the plan for CEO succession after Steve's retirement?  
   **A:** The Board seeks someone to maintain the current strategy and leverage market opportunities.  **[AZTA_3387389_13]**  Steve will support the transition and is confident in the company's future leadership.  **[AZTA_3387389_13]** 

8. **Instruments and Consumables Outlook**  
   **Q:** Are there signs of improvement in Instruments and Consumables?  
   **A:** Consumables bookings were very strong, with significant double-digit sequential and year-over-year increases, reaching the highest levels since the pandemic.  **[AZTA_3387389_20]**  Instruments bookings were soft due to capital spending constraints, but the pipeline is strong and demand is healthy.  **[AZTA_3387389_20]** 

9. **Impact on Future Guidance**  
   **Q:** Does lower 2024 revenue guidance affect 2025 and 2026 outlook?  
   **A:** No, the lower 2024 revenue guidance does not change the 2025 and 2026 guidance.  **[AZTA_3387389_18]**  The company feels confident about the trajectories of Sample Management and Multiomics, expecting continued growth.  **[AZTA_3387389_18]** 

10. **Forecasting B Medical Revenue**  
    **Q:** Can B Medical revenue be better forecasted long-term?  
    **A:** Forecasting B Medical over longer periods remains challenging.  **[AZTA_3387389_12]**  About half of the revenue comes from funding agencies, providing some visibility, but timing of orders is hard to predict.  **[AZTA_3387389_12]**  The vaccine cold chain portion is expected to be around **$100 million** annually with low single-digit growth.  **[AZTA_3387389_12]** 

6049e85b6346e6ccdc933abfc0fcf7e0f42ce0f4be02796637460c940833c9a1

- **Strong growth in the Sample Management Solutions (SMS) and Multiomics segments**, with **large stores growing 50% this quarter** and Multiomics **growing when everybody else is down**, indicating robust demand and effective strategies in these key areas.  **[AZTA_3387389_18]**
- **Significant double-digit increases in bookings** for the Consumables & Instruments business, with **Q2 bookings the highest since the pandemic**, suggesting a rebound in demand and potential future revenue growth.  **[AZTA_3387389_20]**
- **Consistent double-digit growth in China** over the past four quarters, **outperforming the market**, driven by strong local presence and capabilities, leading to increased market share and strengthening global operations.  **[AZTA_3387389_19]**

673eed9e75b13df66d5d75c3592dfa2dfd7dabeedf55d5e88657f32374aee6bd

Adjustments for Non-Cash Items (USD, thousands)

Stock-Based Compensation (USD, thousands)

Changes in Working Capital (USD, thousands)

Capital Expenditures (CapEx) (USD, thousands)

Proceeds from / Repayments of Debt (USD, thousands)

Share Repurchases (USD, thousands)

Dividend Payments (USD, thousands)

Net Change in Cash (USD, thousands)

60f91da1faf49252cd41c59a4437bb81425e84e96a72ee821b203a70fc744089

- **Lowered revenue guidance due to challenges in the B Medical segment:** The company adjusted down its full-year revenue outlook for the B Medical segment, citing unpredictable conversion of its robust pipeline into revenue. This adjustment brings the company's full-year organic revenue guide to a range of negative 1% to positive 1%, reflecting potential stagnation in growth.  **[AZTA_3387389_18]** **[AZTA_3387389_17]** **[AZTA_3387389_9]**
- **Continued headwinds in the Consumables & Instruments business with uncertain recovery timing:** The Consumables & Instruments segment remains challenged due to capital spending constraints and longer purchasing cycles. While the pipeline is strong, the timing of orders remains uncertain, and recovery is dependent on biotech funding, which may lag.  **[AZTA_3387389_20]**
- **Operational delays impacting revenue recognition:** Supply chain delays in the Sample Management Solutions segment are causing orders to be pushed from Q3 into Q4. This indicates operational challenges that may affect quarterly results and revenue predictability.  **[AZTA_3387389_14]**

9b4ad6cdae93895943767fef18b52c32c768ba16cbb3586d5ad01ddb58f5b437

A main competitor in the Sample Management Solutions segment, specifically for automation systems.  **[0001437749-24-036289_azta20240930_10k.htm:8]** 

A main competitor in the Sample Management Solutions segment, particularly for storage, consumables, and services.  **[0001437749-24-036289_azta20240930_10k.htm:8]** 

A main competitor in the Multiomics segment, particularly in genomic services.  **[0001437749-24-036289_azta20240930_10k.htm:8]** 

A main competitor in the B Medical Systems segment, particularly in temperature-controlled storage and transportation solutions.  **[0001437749-24-036289_azta20240930_10k.htm:8]** 

a96b4f74d12851423e6f1e006704b4a471936d5685defff0399bf5e31a8cd8de

Azenta, Inc. is a global leader in life sciences solutions, specializing in the management and exploration of biological and chemical compound samples. The company supports pharmaceutical, biotechnology, academic, and healthcare institutions by providing innovative products and services that enable faster development of therapies and scientific breakthroughs. Azenta's offerings include sample management systems, genomic services, and cold-chain solutions, catering to the growing needs of the life sciences industry.  **[0001437749-24-036289_azta20240930_10k.htm:104]** **[0001437749-24-036289_azta20240930_10k.htm:45]** **[0001558370-24-000902_azta-20231231x10q.htm:32]** **[0001558370-24-007628_azta-20240331x10q.htm:40]** 

1. **Sample Management Solutions (SMS)** - Provides end-to-end sample management products and services, including automated storage systems, cryogenic systems, sample consumables, and repository solutions to ensure sample quality, security, and integrity throughout their lifecycle.  **[0001437749-24-036289_azta20240930_10k.htm:104]** **[0001437749-24-036289_azta20240930_10k.htm:45]** **[0001558370-24-000902_azta-20231231x10q.htm:32]** **[0001558370-24-007628_azta-20240331x10q.htm:40]** 
   - **Sample Repository Solutions (SRS)** - Offers comprehensive storage and management of biological samples.  **[0001558370-24-000902_azta-20231231x10q.htm:32]** **[0001558370-24-007628_azta-20240331x10q.htm:40]** 
   - **Core Products** - Includes automated stores, cryogenic systems, automated sample tubes, and consumables and instruments.  **[0001437749-24-036289_azta20240930_10k.htm:104]** **[0001437749-24-036289_azta20240930_10k.htm:45]** **[0001558370-24-000902_azta-20231231x10q.htm:32]** **[0001558370-24-007628_azta-20240331x10q.htm:40]** 

2. **Multiomics** - Delivers genomics services such as gene sequencing, synthesis, and editing, supporting research in areas like cell and gene therapy, antibody development, and biomarker discovery.  **[0001437749-24-036289_azta20240930_10k.htm:104]** **[0001437749-24-036289_azta20240930_10k.htm:45]** **[0001558370-24-000902_azta-20231231x10q.htm:32]** **[0001558370-24-007628_azta-20240331x10q.htm:40]** 

3. **B Medical Systems** - Specializes in temperature-controlled storage and transportation solutions for cold chain management, including vaccine storage and transport systems.  **[0001437749-24-036289_azta20240930_10k.htm:104]** **[0001437749-24-036289_azta20240930_10k.htm:45]** **[0001558370-24-000902_azta-20231231x10q.htm:32]** **[0001558370-24-007628_azta-20240331x10q.htm:40]**

d4832b7c2eda02cf82ddbe15ac0c3b37e8a3e7a1371e06380cc364b3545f3916

9d5b2ac3e529ec6dc2ef13456f29586254a62d5c079f7717428813545389fb90

| Program Details          | Program 1               |
|--------------------------|-------------------------|
| **Approval Date**        | **November 4, 2022**  **[0001437749-25-003325_azta20241231_10q.htm:19]**  |
| **End Date/Duration**    | **Fully utilized by September 30, 2024**  **[0001437749-25-003325_azta20241231_10q.htm:19]**  |
| **Total Additional Amount** | **$1.5 billion**  **[0001437749-25-003325_azta20241231_10q.htm:19]**  |
| **Remaining Authorization** | **$0** (as of February 20, 2025)  **[0001437749-25-003325_azta20241231_10q.htm:19]**  |
| **Details**              | Repurchased and retired **30.0 million shares** through ASR agreements and open market repurchases. Focused on enhancing shareholder value but prioritized other capital allocation initiatives like R&D, geographic expansion, and M&A.  **[0001437749-25-003325_azta20241231_10q.htm:19]** **[0001558370-22-018195_azta-20220930x10k.htm:21]** **[0001558370-23-014001_azta-20230630x10q.htm:56]** **[AZTA_3414416_15]** **[0001437749-24-036289_azta20240930_10k.htm:53]**  |

4ba30e09f276bfb36f048b6048f288c700e3ae97b60aef855e260e7700b54838

23794d91c53ae875c8e247d72561e35d9d06ee07c70c9e0dbcc977a6d161504a

Azenta (AZTA)

Executives

Board Members

Analyst Coverage